Go to content
UR Home

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

Pouessel, D. ; Neuzillet, Y. ; Mertens, L. S. ; van der Heijden, M. S. ; de Jong, J. ; Sanders, J. ; Peters, D. ; Leroy, K. ; Manceau, A. ; Maille, P. ; Soyeux, P. ; Moktefi, A. ; Semprez, F. ; Vordos, D. ; de la Taille, A. ; Hurst, C. D. ; Tomlinson, D. C. ; Harnden, P. ; Bostrom, P. J. ; Mirtti, T. ; Horenblas, S. ; Loriot, Y. ; Houédé, N. ; Chevreau, C. ; Beuzeboc, P. ; Shariat, S. F. ; Sagalowsky, A. I. ; Ashfaq, R. ; Burger, M. ; Jewett, M. A. S. ; Zlotta, A. R. ; Broeks, A. ; Bapat, B. ; Knowles, M. A. ; Lotan, Y. ; van der Kwast, T. H. ; Culine, S. ; Allory, Y. ; van Rhijn, B. W. G.


Fibroblast growth factor receptor 3 (FGFR3) is a major potential actionable target in urothelial bladder cancer (BC). We found that FGFR3 mutations appeared conserved in primary BC and corresponding lymph-node metastases. We also showed that the deep part of the tumor needs to be assessed if neoadjuvant anti-FGFR3 treatment is considered. This suggests that personalized anti-FGFR3 therapy may ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons